AUROPHARMA IN EQUITY
loading…—
Day range—
52-week range—
Market cap—
P/E · TTM—
As of—
| CUSTOMER | BASIS | EST ₹CR | RANGE | % REV | BUCKET | PERIOD | METHOD | CONF |
|---|---|---|---|---|---|---|---|---|
| Authority. | CONTRACT | CT 7 | — | — | — | FY25 | EST | 75% |
| “2 Nature and details of the action(s) taken, initiated or order(s) passed by the Authority.” ORDER p.2 · 03-MAY-24 DOC | ||||||||
| China. | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “China GMP and USFDA approvals are expected in near term, following which the plant will be positioned as a multi-region supply hub capable of catering three ma…” AR · +2 DOC | ||||||||
| FY27 | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “Commercial supplies into Europe commenced during FY26, with launches for China and the US expected in FY27.” AR DOC | ||||||||
| Parties | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES All transactions entered with Related Parties for the year under review were on arm’s length basis and in the or…” AR · +1 DOC | ||||||||
| Others | UNSTATED | — | — | — | R&D | FY26 | EST | 75% |
| “Board’s Report 203 (iv) Expenditure incurred on Research and development ` Millions 2024-25 2023-24 Capital 66.6 268.0 Recurring 4,881.1 6,021.7 Total R&D Expe…” AR · +1 DOC | ||||||||
| PFIZERPfizer Ltd. | UNSTATED | — | — | — | R&D | FY26 | EST | 75% |
| “I further report that in the Secretarial Audit Report for the year ended March 31, 2024, it was reported that during 2008-09, the Company in the ordinary cours…” AR · +1 DOC | ||||||||
| Parties | UNSTATED | — | — | — | COGS | FY25 | EST | 75% |
| “com/api/uploads/RPT%20Policy-May2025.pdf The particulars of contracts or arrangements with Related Parties referred to in sub-section (1) of Section 188 of the…” AR DOC | ||||||||
| FY27 | UNSTATED | — | — | — | CAPEX | FY27 | EST | 70% |
| “FACILITY BUILD-OUT Construction continued through the year on TheraNym's flagship facility at Borapatla, near Hyderabad, Telangana, encompassing 15 KL bioreact…” AR DOC | ||||||||
| Financial Year | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “Job creation in smaller towns – Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent / on contract …” AR · +1 DOC | ||||||||
| Securities and Exchange Board of India | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “and Annexure-B Secretarial Compliance Report of Aurobindo Pharma Limited for the financial year ended 31st March 2025 (Pursuant to Regulation 24A of SEBI (LODR…” AR · +1 DOC | ||||||||
| Others | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “Effect of : Expenses not deductible for tax purposes 181.0 265.3 Dividend received from subsidiaries - (666.1) Deferred tax reversal on account of transfer of …” AR · +1 DOC | ||||||||
| Others | UNSTATED | — | — | — | SG&A | FY26 | EST | 70% |
| “OTHER FINANCIAL ASSETS (Unsecured, considered good unless stated otherwise) (A) Non current As at March 31, 2025 As at March 31, 2024 Security deposits Conside…” AR · +1 DOC | ||||||||
| Office | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “GRI 418: Customer Privacy 2016 418-1 Substantiated complaints concerning breaches of customer privacy and losses of customer data ESRS S4 S4-3 $ 15, $16 This t…” AR DOC | ||||||||
| SUPPLIER | BASIS | EST ₹CR | RANGE | % COST | BUCKET | PERIOD | METHOD | CONF |
|---|---|---|---|---|---|---|---|---|
| China. | UNSTATED | — | — | — | COGS | FY25 | EST | 75% |
| “44% of our raw-material requirement (APIs plus Excipients) is procured from China (including Hong Kong), 9% from other countries, and the remaining 47% from th…” AR DOC | ||||||||
| AADHARHFCAadhar Housing Finance Ltd. | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “Presently, she is serving as a Director in Tata Capital Ltd., Tata Asset Management Private Ltd., Ventive Hospitality Ltd., Aurobindo Pharma Ltd., One Mobikwik…” AR DOC | ||||||||
| Renewable Energy | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “UN SDGs KEY FOCUS AREAS KEY HIGHLIGHTS FY26 RENEWABLE ENERGY SHARE (POWER TO POWER) 18.4% TREATED WASTEWATER REUSED 22% KEY STARTING MATERIAL SUPPLIERS ASSESSE…” AR DOC | ||||||||
| China. | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “The growing popularity of China plus one strategy among large pharmaceutical markets, is paving way for India to further emerge as a key global pharmaceutical …” AR · +1 DOC | ||||||||
| Office | UNSTATED | — | — | — | COGS | FY25 | EST | 70% |
| “70%of spending on local suppliers for key raw materials 86%of spending on local-local suppliers for key raw materials Multisite RSPO Supplychain Certification …” AR DOC | ||||||||
| SOURCE | READ | % | LAST READ |
|---|---|---|---|
| ANNOUNCEMENTS | 1/1 | 100% | 15-OCT-26 |
| ANNUAL | 2/2 | 100% | 15-OCT-26 |
| CONCALL | 4/4 | 100% | 15-OCT-26 |
| ORDERS | 1/1 | 100% | 15-OCT-26 |
| SCREENER | 1/1 | 100% | 08-NOV-26 |
| SIGNAL | VALUE | AS OF | INPUTS |
|---|---|---|---|
| CUST MOM 1M | +0.9% | 15-NOV-26 | from 16-OCT-26 · Pfizer Ltd. +0.9% |
| DISTRESS SCORE | 0.220 | 13-OCT-26 | roe 0.09 · operatingMargin 0.2 · debtToEquity 0.21 · interestCoverage 14.31 · assetTurnover 0.58 · leverage 1.54 |
| SUPP MOM 1M | -3.2% | 15-NOV-26 | from 16-OCT-26 · Aadhar Housing Finance Ltd. -3.2% |